Pharmeca.cz

When determining the maximum price and the reimbursement level of medicinal products in the Czech Republic, the principle of external price referencing (EPR) is applied. The principles of external price referencing in the Czech context are set out in Act No. 48/1997 Coll., on Public Health Insurance and on Amendments and Supplements to Certain Related Acts.

The foundation of this approach is the comparison of the ex-factory prices of a given medicinal product across EU countries, with the final maximum price in the Czech Republic derived based on these references. It is important to note that EPR conditions and methodologies vary across the EU and a uniform approach has not yet been adopted. Each country has its own specific rules and lists of countries it references in its EPR system.

To support understanding, we have created an interactive map that visualizes the countries involved in the EPR system as applied in the Czech Republic. This tool provides a quick overview of which countries are considered when determining the maximum price and the reimbursement level of medicinal products in the Czech setting.

🔍 Map features:

• Display of countries used as reference when determining reimbursement levels
• Overview of national price databases
• Distinction between countries used in the reference basket for the manufacturer’s maximum price
• Clear color coding for easy navigation

This map is a useful tool for:

• Professionals in the pharmaceutical industry
• Health policy analysts
• Pricing and reimbursement regulators
• And anyone interested in the dynamics of European pharmaceutical pricing strategies

👉 The interactive map is available here     

Starting january 1, 2025, Pharmeca a.s. will provide an overview of issued decisions by the State Institute for Drug Control (SÚKL) and the Ministry of Health of the Czech Republic (MZ ČR) related to pricing and reimbursement on its website.

For marketing authorization holders, knowledge of SÚKL and MZ ČR decisions in the area of pricing and reimbursement is essential. The outcomes of individual proceedings shape decision-making practices that influence future decisions.

To address this need, Pharmeca a.s. now offers an interactive overview of decisions issued in the past five weeks.

Drug pricing and reimbursement are based on price referencing, where the foreign price in a foreign currency is converted into Czech koruna. For this purpose, it is essential to obtain the quarterly average exchange rate for the foreign exchange market, as published by the Czech National Bank.

Our new online overview provides:
✔ The required average exchange rate from the previous quarter
✔ The exchange rate development in the current quarter
✔ A monitoring focus on the 7 most commonly used European exchange rates in administrative proceedings

And all of this at a click!